Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVEC-119: Sequential Therapy in R/M HNSCC
NCT06869473Phase 2Recruiting
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Feb 2025
- Primary completion
- Aug 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Gruppo Oncologico Nord Ovest. Primary endpoint: Progression-Free Survival at 6 months. Started Feb 2025; status: recruiting.
02
Drugs
avelumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06869473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06869473.